These liposomes generally have a small mean particle size of about 70-120 nm. This size range is optimal for many in vivo applications, where smaller liposomes may have enhanced tissue penetration and distribution properties.
PEGylation, achieved with DSPE-mPEG2000, enhances the stability and circulation time of these liposomes in the bloodstream. This modification reduces the immune system clearance, thus potentially increasing the bioavailability of encapsulated drugs.
Yes, due to their versatile lipid composition, these liposomes can encapsulate a wide range of drug molecules, including both hydrophilic and hydrophobic compounds. This makes them highly suitable for diverse drug delivery applications.
These liposomes are especially useful in studies involving targeted drug delivery, including cancer therapy, due to their ability to carry and release drugs at specific sites. The PEGylation helps in evading the host's immune system, allowing the liposomes to circulate longer in the bloodstream.
The liposomes are produced under stringent conditions to ensure high purity and sterility. The production process includes steps such as sterile filtration, and they are generally provided in glass vials to maintain their integrity and quality during storage and handling.
Therapeutic effects of cisplatin/mifepristone co-encapsulated liposomes on cervical cancer in vivo and in vitro.
This study examined the therapeutic effects of co-encapsulated liposomes on cervical cancer both in vivo and in vitro. Researchers utilized HSPC:Chol:DSPE-mPEG2000 liposomes as carriers to co-encapsulate cisplatin (Cis) and mifepristone (MF), resulting in the formation of L-Cis/MF. The therapeutic effects of L-Cis/MF on hela cells and xenografts in nu/nu mice were investigated. Figure A demonstrates that drug-loaded liposomes induced higher levels of apoptosis compared to free drugs. Figure B shows that the tumor growth inhibition of drug-loaded liposomes was superior to that of free drugs, with L-Cis/MF exhibiting the most pronounced effect. This study presents an effective, stable, and sustained drug delivery strategy for cervical cancer treatment, demonstrating superior therapeutic outcomes both in vivo and in vitro.
Ledezma-Gallegos, Fabricio, et al. "Liposomes co-encapsulating cisplatin/mifepristone improve the effect on cervical cancer: in vitro and in vivo assessment." Pharmaceutics 12.9 (2020): 897. Under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
Online Inquiry